An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

As we previously reported, JAMP sought leave to commence an application against Janssen under the abuse of dominance ...

Bengaluru-based biopharma firm Biocon on Thursday reported a consolidated net profit of Rs 25.1 crore in the third quarter of the financial year 2024-25 (Q3FY25). During the same period in the ...

While you wait for the groundhog to make his determination this weekend, take some time to buff up your knowledge of rheumatoid arthritis, a chronic autoimmune disease that affects about 1.5 million ...

The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by ...

SEOUL, Jan. 23 (Korea Bizwire) — Celltrion Inc.’s autoimmune disease treatment, SteQeyma, has been launched in five major ...

On December 17, 2024, the Competition Tribunal (the Tribunal) issued reasons for its decision to dismiss an application for leave to bring a ...

The J&J deal would be the biggest biotech deal in over a year and will add treatments for disorders of the central nervous ...

The second round of Medicare Part D price negotiations will feature two drugs familiar to rheumatologists — Ofev and Otezla — ...

Celltrion's ustekinumab biosimilar is now available in France, Italy, Spain, Britain and Germany after securing European ...

In the pivotal trial, patients treated with Omvoh experienced significant improvements in clinical remission and endoscopic ...